Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 12/14/2016
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||K009460 / 0||UN / UN|
Administered by: Other Purchased by: Other
Symptoms: Epilepsy, Generalised tonic-clonic seizure, Petit mal epilepsy
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Other Medications: No other medications
Current Illness: Immunisation
Preexisting Conditions: Febrile convulsion, medical continue; unknown; Pertussis vaccine (unspecified)
Diagnostic Lab Data:
CDC 'Split Type': WAES1607DEU008037
Write-up:Information has been received from a consumer via SPMSD (case reported number DE-1577272925-2016007325) on 18-JUL-2016. Case received on 12-Jul-2016. A 15-year-old female adolescent patient received GARDASIL (lot and batch number K009460, Dose 1, expiry date: Sep 2016) on 31-Mar-2015, GARDASIL (lot and batch number K022803, dose 2, expiry date: Nov 2016) on 03-Jun-2015. The patient experienced epilepsy on April 2015. Starting in April 2015, first petit mal occurred. Starting in September 2015, worsening to grand mal. Meanwhile manifest epilepsy was diagnosed. The patient had a medical history of febrile seizure and received Pertussis vaccine. The patient''s outcome was reported as Not Recovered/Not Resolved. The reporter assessed the causal relationship between epilepsy and GARDASIL as unknown. The rechallenge result is positive.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166